SS-31 (Elamipretide)

What it is

SS-31 (elamipretide) is the first FDA-approved mitochondrial-targeted peptide. That sentence alone moves it above almost everything else in the longevity cluster: on September 19, 2025 the FDA granted accelerated approval to FORZINITY (elamipretide injection), sponsored by Stealth BioTherapeutics, to improve muscle strength in adult and pediatric patients with Barth syndrome weighing ≥30 kg: an ultra-rare genetic cardiolipin disorder affecting roughly 150 people in the US — and the trial data behind that approval, plus four other large human trials in other indications, gives SS-31 ~475 patients of published human safety data across exposures up to 168 weeks at 40 mg/day SubQ with ZERO serious adverse events. That’s a cleaner record than nearly any other longevity peptide.

Underneath the FDA-approval headline is something more interesting: a fundamentally different mechanism than every other peptide in this wiki. SS-31 doesn’t signal anything. It doesn’t bind a receptor. It doesn’t activate a growth pathway. It doesn’t modulate the immune system. It’s structural support — a positively-charged 4-amino-acid peptide that binds the negatively-charged phospholipid cardiolipin in the inner mitochondrial membrane, stabilizes it, and breaks the ROS-damage vicious cycle that is arguably the root engine of aging itself. “Structural support, not signaling” is Stillson’s framing, and it changes the safety calculus completely (more on that below).

The cleanest mitochondrial-peptide taxonomy comes from Stillson:

• Mitochondrial-DERIVED peptides = naturally produced by your mitochondria. MOTS-c and Humanin are the main two. They are signaling molecules your mitochondria already make.
• Mitochondrial-TARGETED peptides = synthetic, specifically designed to act on mitochondria. SS-31 / elamipretide is the prototype.

These are different mechanism categories that both belong in a serious mitochondrial protocol, doing complementary jobs. MOTS-c signals “build more mitochondrial machinery and burn fat.” SS-31 stabilizes the machinery you already have so it stops leaking electrons and damaging itself. The two are a stack, not a substitution.

How it works

Start with the problem SS-31 solves. The electron transport chain (ETC) lives on the inner mitochondrial membrane and is what generates ~90% of your cell’s ATP. The ETC is also where the vast majority of your reactive oxygen species (ROS) are produced — every working ETC leaks some electrons, those electrons become ROS, and ROS damage everything around them, especially the inner mitochondrial membrane itself.

The inner mitochondrial membrane is stabilized by cardiolipin, a uniquely-shaped, negatively-charged phospholipid. Cardiolipin holds the ETC complexes in place and is required for the membrane geometry the ETC needs to work efficiently. ROS damage cardiolipin. Damaged cardiolipin destabilizes the ETC. Destabilized ETC leaks MORE electrons. More electrons → more ROS → more cardiolipin damage → more ETC dysfunction → vicious cycle, snowball effect, accelerating mitochondrial failure. This is the engine that arguably drives much of aging, neurodegeneration, heart failure, kidney decline, and metabolic disease.

A second threat: the immune-attack loop. ROS-mediated damage is one path to cardiolipin failure. There’s a second, immunologically driven path that gets much less attention. When mitochondria are badly stressed — by illness, poor metabolic health, toxic exposures, or chronic inflammation — damaged cardiolipin can leak out of both the inner and outer mitochondrial membrane and into the extracellular space. The immune system encounters it there and treats it as foreign (cardiolipin belongs inside mitochondria; finding it outside is anomalous). In response, the immune system begins producing anticardiolipin antibodies, which then attack cardiolipin on intact mitochondria — accelerating the vicious cycle from the outside.

This matters clinically in three ways. First, multiple small studies have found elevated anticardiolipin antibody prevalence in chronic fatigue syndrome patients, raising the question of whether CFS with normal labs may sometimes be a mitochondrial-immune story rather than purely a metabolic one. Second, people carrying anticardiolipin antibodies are susceptible to microvascular attacks — small blood clots in the fine vessels feeding highly mitochondrially-dense tissue: kidneys, eyes, brain. These hypoperfusion injuries, not just direct mitochondrial failure, may be the mechanism behind SS-31’s documented benefits across kidney, eye, brain, and cardiac function in human trials — it’s not only stabilizing mitochondria directly, it’s enabling reperfusion of tissue that was starved of blood flow. Third, anticardiolipin antibodies can rise in severity, with higher-burden states associated with larger vessel thrombosis (heart attacks, strokes) in antiphospholipid syndrome. Around 10% of healthy people may carry these antibodies at low levels, and they commonly appear transiently during viral or bacterial infections — potentially explaining why some people never fully recover their energy after a bad illness.

SS-31 addresses this immune loop through two complementary mechanisms. First, it binds to cardiolipin and acts as a physical barrier against antibody attachment — essentially shielding cardiolipin from immune attack at the surface. Second, it blocks the opening of the outer mitochondrial membrane, preventing mitochondrial swelling and stopping cardiolipin from being extruded into the extracellular space where the immune system can reach it in the first place.

SS-31 breaks the cycle. It’s a tetrapeptide with a net positive charge — it’s electrostatically drawn to negatively-charged cardiolipin, accumulates in the inner mitochondrial membrane, binds cardiolipin, and stabilizes it. Stable cardiolipin → stable ETC → less electron leak → less ROS → less cardiolipin damage → more ATP. The vicious cycle becomes a virtuous one. SS-31 doesn’t activate the ETC, doesn’t push more electrons through, doesn’t signal anything to anyone — it’s structural support. That’s it. That’s the whole mechanism.

Why “structural-support-not-signaling” matters for safety. This is Stillson’s key insight, and it changes the safety calculus fundamentally:

• No cancer-promotion concern. No growth signaling, no receptor activation, no proliferation pathway. The theoretical-tumor-promotion concern that applies to BPC-157 (VEGF, FAK-paxillin) doesn’t apply here at all.
• No immune-dysregulation concern. No immune-pathway involvement. The PD-1-contraindication-class concern that applies to Thymosin Alpha-1 doesn’t apply here.
• No mitochondrial-overstimulation concern. SS-31 just stabilizes; it doesn’t activate. You can’t overdrive what you’re only holding in shape.
• No tachyphylaxis or tolerance. No receptors involved means no receptors to downregulate or desensitize. Continuous use doesn’t lose effect over time.

This is fundamentally a different safety profile than every other peptide in this wiki. Lift this framing for any SS-31 content.

What the research shows

Human evidence: extensive and unusually clean.

• Barth syndrome 10-patient extension trial: patients dosed at 40 mg SubQ daily for 168 weeks (over 3 years). Outcomes: 30–40% improvement in muscle strength and functional markers, ~50% improvement in heart function markers. Only adverse events: local injection-site reactions. This is the trial set that anchors the FDA approval.
• 218-patient mitochondrial-disorder safety trial — 40 mg SubQ daily × 24 weeks. Only AEs: injection-site reactions.
• 176-patient macular degeneration trial — 40 mg SubQ daily × 48 weeks. Only AEs: injection-site reactions. Outcome: didn’t show large effects on the macular endpoints — a negative-efficacy finding for that indication, but adds to the safety record.
• 71-patient heart failure trial — 4–40 mg SubQ daily × 28 days. Only AEs: injection-site reactions. Outcome: didn’t show meaningful effect on heart-failure endpoints in that population.
• Phase 2 CKD trial: SS-31 + renal-artery stenting — significantly improved kidney function vs. stenting alone in renal-artery-stenosis patients.

Total documented human exposure: ~475 patients across long-term trials. Zero serious adverse events. This is one of the strongest human safety profiles for any peptide in the KB.

Animal / preclinical: first-class evidence. Stillson’s clinical-priority ranking by evidence quality:

• Top tier: most excited (mechanistically and preclinically strongest, no human data yet):
  • Neurodegenerative disease (Alzheimer’s, dementia, cognitive decline) ✅ verified 2026-06-18 — multiple recent preclinical papers anchor this lane: GeroScience 2025 (“Aging, mitochondrial dysfunction, and cerebral microhemorrhages: preclinical evaluation of SS-31 and a high-throughput ML-driven imaging pipeline for cerebromicrovascular protection”) + the 2025 elamipretide review in Int J Mol Sci (PMC11816484) summarizing SS-31’s neuroprotective action via reduced mitochondrial swelling, reduced neuronal loss, decreased neuroinflammation across TBI / Alzheimer’s / Parkinson’s models. Important caveat: NO completed human dementia or Alzheimer’s trial yet — this is a preclinical-tier signal with strong mechanism, not a confirmed human therapy for cognitive decline. The Alzheimer’s-prevention framing is biologically defensible but human-trial-pending.
  • Traumatic Brain Injury (TBI) ✅ verified 2026-06-18 — mouse studies showing decreased post-injury brain damage + functional recovery (same MDPI 2025 review covers TBI mechanism + outcomes).
• Close second:
  • Chronic Kidney Disease (CKD) — multiple mouse models (diabetic, age-related, obesity-driven) plus the Phase 2 stenting human trial above.
• Moderate: works but cheaper alternatives exist:
  • Diabetes / insulin resistance — mouse studies show effect; for most patients, MOTS-c / GLP-1s / standard insulin sensitizers are more cost-effective.
• Speculative but mechanism-plausible (anecdotal + mechanism only, no trials):
  • Chronic fatigue / Long COVID / post-viral syndromes — anecdotal patient reports + human ATP-improvement data; the mechanism (broken mitochondria → fatigue) is strong but no direct intervention trials exist. An additional layer: some studies have found elevated anticardiolipin antibody prevalence in CFS populations. If anticardiolipin antibodies are contributing to fatigue via mitochondrial immune-attack and/or microvascular hypoperfusion, SS-31 addresses both paths simultaneously. This also explains why some patients with entirely normal standard bloodwork respond to SS-31 — the relevant pathology (antibody-mediated cardiolipin damage) isn’t on a standard metabolic panel. The clinical question worth asking: should patients with unexplained chronic fatigue be screened for anticardiolipin antibodies? [OPINION — Froese 2026; not yet standard-of-care]
• Less excited (negative or null human data):
  • Heart failure (71-patient trial null).
  • Macular degeneration (176-patient trial null).
• Other plausible: eye diseases, certain genetic mitochondrial disorders, fibromyalgia.

The age-stratification finding: critical for anti-aging use. Stillson: young mice (human-equivalent 20–30 years) given SS-31 showed NO positive effects. Mitochondrial dysfunction begins meaningfully at mouse-age 18 months ≈ human ~50 years. This is a peptide where the indication is “declining mitochondria,” and if your mitochondria are still working well, there is nothing for SS-31 to stabilize that wasn’t already stable. Don’t take SS-31 “just in case” in your 20s or 30s. The clinical recommendation is age 50+ OR lab-confirmed mitochondrial dysfunction at younger ages.

Where the evidence is thin. No long-term human longevity-cohort data (Russian-school or otherwise). The Phase 3 trials that exist are in specific disease populations (Barth, macular degeneration, heart failure, CKD), not in healthy aging adults — so the “does it extend healthspan in normal aging?” question rests on the animal data + the mechanism + the safety record + the early human Long COVID / chronic-fatigue anecdotal reports. That’s promising. It’s not proven the way the Barth indication is.

Real-world lower-dose tracking (case-study data, 1–2 mg range).

The clinical trial doses above (40 mg/day) are far above what most self-directed users will run. The only KB data at the 1–2 mg range comes from a self-tracked biohacker who followed five subjects and tracked mitochondrial biomarkers via the “True Health” diagnostic platform before and after SS-31 cycles of 60–70 days.

ATP5B (ATP synthase β-subunit — mitochondrial efficiency marker): In this tracking system, a lower score indicates less mitochondrial ETC stress. Average across the five subjects: ATP5B improved 18.5 points (moved toward the low-stress zone). A comparable MOTS-C case series on the same platform (N=4) showed ~9.5 points — SS-31 roughly double the ATP5B effect.

DRP1 (Dynamin-1-like protein — mitochondrial fusion/fission dynamics): Optimal target is the ~50th percentile — balanced between mitochondrial fusion and fission. Too high = mitochondrial fragmentation from oxidative stress, inflammation, or calorie excess. Too low = excessive fusion, impaired mitophagy, metabolic disease signal. SS-31 moved DRP1 by +7 points average toward the 50th percentile. The same MOTS-C series moved DRP1 by ~13 points — MOTS-C appears to have more impact on dynamics while SS-31 leads on efficiency.

Glucose and HbA1c (epigenetically measured): Glucose improved an average of 8 points; HbA1c improved 6 points. Highly individualized — one person improved 38 points on glucose, another was essentially neutral (already metabolically healthy). People at the higher end of the dose (2 mg vs. 1 mg) showed consistently bigger improvements across all markers. ]

Practical implication: At 1 mg/day the response is real but weak; 2 mg/day is the dose that moves markers meaningfully in self-tracked data. This is consistent with Williams’s “optimization tier” bottom (1–2 mg/day) and the observation that “the difference between 2 and 10 mg was not even that much” once metabolically fit. The 2 mg/day floor appears to be the accessible, minimum-effective dose for this population.

Important confounders: calorie excess (~500 cal/day over maintenance) can fully negate the mitochondrial benefits — it drives up reactive oxygen species at a rate that outpaces SS-31’s stabilization effect. Toxin exposures (glyphosate cited) can also elevate DRP1 independently. Metformin use (mitochondrial complex I inhibitor) may suppress the same ETC markers SS-31 is improving. Any self-tracker using SS-31 while in a calorie surplus should not expect strong results.

Real-world protocol

The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only outside their FDA-approved indication. This is not medical advice. Consult a qualified physician before beginning any protocol.

The protocol Stillson actually runs and recommends.

• Dose (Stillson’s clinical recommendation): Start at 5–10 mg/day SubQ. Increase in 5 mg increments. Max 40 mg/day (the dose used in all the long-term human trials).
• Route: Subcutaneous only. IV has been used in trials but SubQ is the standard. Do not use oral SS-31 — there is no human and no animal data on oral SS-31, and 4-amino-acid peptides don’t fit the di-/tri-peptide intestinal transporters, so oral absorption is expected to be poor. Stillson is direct: do not trust unsubstantiated oral SS-31 formulations.
• Frequency: Daily. SS-31 clears plasma in ~24 hours but accumulates in mitochondria — some studies used 2×/week successfully, but Stillson prefers daily 5–10 mg over 2×/week 17.5 mg for continuous support.
• Cycles: Stillson’s recommendation: 1 month on / 1 month off baseline. Human trials used SS-31 continuously for up to 168 weeks without tachyphylaxis or tolerance loss: there’s no biological reason to cycle. The 1-on/1-off recommendation is for skin recovery from daily injection sites + cost management, not biology.

Cost framing (this is the Alyve commercial unlock).

• Compounded SS-31 is approximately $1 per mg at higher quantities.
• 40 mg/day = $40/day ≈ $1,200/month — not sustainable for most people.
• 5–10 mg/day = $5–10/day = $150–300/month — the customer-accessible entry point and the actual Stillson clinical recommendation.

The clinical-trial dose was set for the most severe mitochondrial-dysfunction population on Earth (Barth syndrome). For anti-aging or post-viral or early-CKD use, 5–10 mg/day is the protocol — and at that dose, SS-31 becomes accessible at sustainable monthly cost.

Reconstitution math. SS-31 typically ships as a lyophilized powder, commonly 20 mg or 50 mg vials. For a 20 mg vial reconstituted with 2 mL bacteriostatic water, you get 10 mg/mL — and 5 mg = 0.5 mL = 50 units on a U-100 insulin syringe; 10 mg = 1 mL = 100 units (full syringe). For a 50 mg vial reconstituted with 2.5 mL bac water, you get 20 mg/mL — and 10 mg = 0.5 mL = 50 units. Inject water down the side, swirl gently, never shake. Reconstituted SS-31 stores in the fridge.

Source preference. Stillson explicitly prefers compounding pharmacy > research-use-only sites — directly aligned with the Alyve verified-vendor framing.

Stacking: the mitochondrial-defense cluster.

• MOTS-c — the mitochondrial-DERIVED partner. MOTS-c signals “build more mitochondrial machinery, burn fat, restore insulin sensitivity”; SS-31 stabilizes the machinery you already have. Mitochondrial-signaling + mitochondrial-structural.
• NAD+ — supports the glutathione cycle and the redox systems that neutralize ROS. SS-31 prevents ROS production at the ETC; glutathione + NAD-supported antioxidant defense neutralizes the ROS that still gets made. Synergistic.
• Glutathione (when added to the longevity branch) — the same redox-defense pair as NAD+.
• Epithalon — the genomic / telomere layer. Mitochondrial + genomic = the two clocks of cellular aging.
• Thymosin Alpha-1 — the immune-surveillance layer.
• SLU-PP-332 (exercise mimetic) — a synthetic small-molecule pan-ERR agonist (ERRα, ERRβ, and ERRγ; developed at Saint Louis University) that drives mitochondrial biogenesis by activating PGC-1α — the master transcriptional coactivator of mitochondrial biogenesis, fatty acid oxidation, and oxidative phosphorylation. It reproduces many of the gene-expression changes of aerobic exercise. Self-tracked users run SLU-PP-332 at ~3 mg alongside or preceding SS-31 cycles. Note: published mouse doses are ~25–50 mg/kg; the 3 mg human community dose has no published human trial behind it. Not a peptide but increasingly stacked with SS-31 in the mitochondrial optimization community.
• The full mitochondrial-defense + restoration stack: SS-31 + MOTS-c + NAD+ + glutathione (and Epithalon + Thymosin Alpha-1 for the wider longevity-restoration cluster, BPC-157 for repair). SLU-PP-332 may be layered in for biogenesis during the SS-31 cycle. MOTS-c stacking timing — sequential vs. concurrent — depends on the user’s baseline; see the stacking update in the cycling section below.

Age-stratified protocol guidance.

• Under 50, no clinical indication, no lab evidence of mitochondrial dysfunction: SS-31 is probably not for you yet. The mouse data is clear — young animals showed no benefit. Better use of money in the longevity cluster: build the foundation (BPC-157, MOTS-c, NAD+, Epithalon on cycle) before adding SS-31.
• 50+ OR lab-confirmed mitochondrial dysfunction at any age: 5–10 mg/day SubQ, 1 month on / 1 month off, alongside the mitochondrial-defense stack.
• Diagnosed mitochondrial-genetic disease (Barth syndrome, certain LHON variants): This is the FDA-approved indication; clinical management is appropriate.
• Post-TBI, post-COVID, post-viral chronic fatigue: Mechanism strong, evidence anecdotal — defensible to try at 5–10 mg/day for a 2–3-month trial with patient-reported outcomes as the monitoring metric.

A nuance worth understanding for the autoimmune-fatigue use case. SS-31 doesn’t touch the immune system directly — no T-cell modulation, no NK-cell activation, no PD-1-class concern. That’s a feature, not a limitation. But there’s a secondary connection worth surfacing: the immune system is energetically expensive to run. Mounting an inflammatory response, producing cytokines, sustaining the metabolic surge of an autoimmune flare — all of this depends on ATP availability at the cellular level. Patients running chronic-autoimmune-fatigue presentations (Hashimoto’s flares, lupus exhaustion, MS-related fatigue, long-COVID with autoimmune overlap, fibromyalgia) often describe their fatigue as both the symptom of the disease AND the consequence of running an over-active immune system on under-performing mitochondria. SS-31’s mitochondrial stabilization can support the energetics underneath an immune system already working too hard — not by modulating immune signaling, but by giving the cellular machinery more ATP to do its job. This is mechanism-plausible, not trial-confirmed in autoimmune populations specifically, but it explains why patients with the autoimmune-fatigue presentation often respond well to SS-31 even though it’s not “treating” the autoimmune disease. For the autoimmune-on-GLP-1 patient population covered in Low-Dose Naltrexone (LDN) — the immune-modulation bridge for autoimmune patients on GLP-1s, SS-31 fits as an optional cellular-energy adjunct for the chronic-fatigue side of the presentation.

Williams’s 3-tier dosing framework — a complementary practitioner read of the population-by-dose mapping, with named indications per tier:

Tier	Population	Dose
Optimization tier	Already healthy, “last 5%” performance / longevity	1–2 mg/day
Metabolic-dysfunction tier	Overweight, history of heart disease, prediabetic, post-COVID	2–5 mg/day
Severe-chronic tier	Lyme disease, fibromyalgia, chronic fatigue, autoimmune, long COVID — “very bad mitochondrial function”	10 mg/day
Cardiologist-cited extreme	Severe heart disease, 60-day needle-moving window	20 mg/day
FDA-approved trial dose	Barth syndrome	40 mg/day

Williams’s clinical observation that goes with this: healthier individuals saturate at lower doses — the dose-response is bounded. He personally found “no meaningful difference between 2–3 mg/day and 10 mg/day” once metabolically fit, suggesting there’s a per-person ceiling above which extra dose stops moving the needle. The framework is consistent with Stillson’s 5–10 mg/day baseline (which maps to optimization → metabolic-dysfunction tiers) and extends it down (1–2 mg/day for already-healthy users) and up (10–20 mg/day for severe chronic disease where benefits compound over months). Pick the tier that matches the use case, not the bigger-is-better default.

The “no-receptor → year-round-OK” cycling principle. Williams’s central biology-led argument for chronic SS-31 use: SS-31 has no classical receptor. Unlike GLP-1 RAs that down-regulate their receptors with repeated stimulation (which is why people need to escalate Reta/semaglutide doses), SS-31 binds cardiolipin directly in the inner mitochondrial membrane — a structural target, not a receptor. No receptor → no desensitization. The Barth syndrome clinical trial data backs this clinically: patients used SS-31 daily for up to 168 weeks (over 3 years) at 40 mg/day with no serious AEs and no loss of effect. The standard “cycle every peptide 8–12 weeks on, 8–12 weeks off” rule is biologically warranted for receptor-binding peptides; for SS-31 it isn’t. Stillson’s 1-on / 1-off recommendation is for skin recovery from daily injection sites and cost management, not biology (already noted above). Williams’s longer-standing position — always-on SS-31 at the optimization tier (1–2 mg/day) with 8–12 week MOTS-c cycles overlaid 1–2× per year — remains valid. A March 2026 study (Gudiksen & Pilegaard, PMID 41520850) adds a second defensible approach for the optimization tier: running SS-31 and MOTS-c concurrently from day one.

The reasoning: the study confirmed MOTS-c has its own direct ROS-reduction effect — not only a “build more mitochondria” signal, but an independent oxidative-protection layer (PGC-1α/AMPK dependent) that reduces ROS emission and the protein damage that follows. That means SS-31 and MOTS-c are addressing the same root problem through completely different mechanisms: SS-31 via cardiolipin stabilization → reduced electron leak → less ROS at the structural membrane level; MOTS-c via functional-efficiency improvement + its own ROS-reduction pathway. Two angles, same target, no mechanistic redundancy.

Stacking timing by user tier:

Baseline	Recommended MOTS-c timing
Severe mitochondrial dysfunction (chronic fatigue, long COVID, metabolic disease)	Sequential — SS-31 first to establish structural repair; add MOTS-c once the foundation is working
Optimization / maintenance (otherwise healthy, longevity-focused)	Concurrent from day one — both compounds running simultaneously is now well-supported

Optional prefatory step: urolithin A before SS-31. [OPINION — Froese 2026; not a tested protocol] A more complete three-step framework is: urolithin A first (stimulates mitophagy — the cellular process that clears out old, failing mitochondria before they become a liability), then SS-31 (stabilizes the healthier mitochondria that remain, now that the worst-functioning ones have been cleared), then MOTS-c (drives biogenesis to build fresh mitochondria on a now-stable foundation). The logic is: stabilizing a failing population and building more copies of it is less effective than clearing the failing units first, then stabilizing and expanding what remains. The urolithin A step is optional and most relevant for the severe-dysfunction tier where old mitochondria have accumulated significantly; for the optimization tier already running concurrent SS-31 + MOTS-c, it’s less impactful.

Pair with the MOTS-c framing: SS-31 handles the structural hardware layer; MOTS-c handles the signaling + functional-efficiency + oxidative-protection software layer. The 2026 data established these are genuinely different mechanisms — not the same lever pushed twice.

SS-31 as injectable “broad-spectrum mitochondrial support” — Williams’s red-light analogy. Because SS-31 hits the structural integrity of mitochondria, and mitochondria are densest in cardiac tissue, retinal tissue, brain, kidneys, and liver, it shows up broadly across organ systems rather than as a single-receptor effect. Williams’s frame: “If you could inject red-light therapy, SS-31 would be the closest thing to that.” Useful framing for explaining the breadth of reported clinical observations: kidney function (eGFR up), prostate volume / PSA observations in older men, migraine reduction (~30 days), recovery / HRV improvements in athletes — all consistent with hitting mitochondrially-dense tissues simultaneously rather than acting through one specific pathway.

Side effects & management

SS-31 has arguably the cleanest safety record in the entire peptide longevity cluster. Across 475+ documented patients exposed up to 168 weeks at 40 mg/day SubQ in long-term published trials, zero serious adverse events. The only consistent finding: injection-site reactions (mild redness, occasional irritation).

Why the safety profile is structurally different. Per the “structural support, not signaling” mechanism:

• No cancer-promotion concern — no growth signaling.
• No immune dysregulation — no immune pathway.
• No mitochondrial overstimulation — just stabilization, no activation.
• No tachyphylaxis or tolerance — no receptors to downregulate.
• No documented withdrawal syndrome.

Injection site comparison with MOTS-C: SS-31 produces noticeably lighter injection-site reactions than MOTS-C — redness at the injection site is a common MOTS-C complaint but is much less frequent with SS-31.

Management:

• Rotate injection sites. This is the only consistently reported issue.
• The 1-month-on / 1-month-off cycle is largely to give the skin a break, not biology.
• If you are pregnant or trying to conceive: the data hasn’t been generated; defer.
• Genetic mitochondrial disease management: the Barth syndrome indication is the FDA-approved use case and is appropriately managed clinically.

Cost is the real limiter, not safety. At 40 mg/day the protocol runs ~$1,200/month, which is not where most people will land. At 5–10 mg/day it’s $150–300/month and accessible. The right dose is “the lowest dose that produces a meaningful effect,” which for most non-Barth users is in the 5–10 mg range.

Regulatory status

🎯 FDA accelerated approval, September 19, 2025: FORZINITY (elamipretide injection), Stealth BioTherapeutics. ✅ Verified (FDA press announcement + Stealth press release). Approved indication: improve muscle strength in adult and pediatric Barth syndrome patients ≥30 kg. First FDA-approved mitochondrial-targeted peptide. Stealth is studying elamipretide in further indications (dry age-related macular degeneration, primary mitochondrial myopathy).

For off-label use, SS-31 sits in the research-chemical / compounded-peptide space the rest of this wiki covers. The FDA approval for Barth syndrome gives the molecule a regulatory anchor — it’s a real drug with a real label, not just a research chemical — which is a notable differentiator vs. every other compound in the longevity cluster.

The Alyve product

SS-31 is not in Alyve’s current launch catalog of 15 SKUs: top-tier roadmap candidate alongside Thymosin Alpha-1 and Kisspeptin (the three “FDA-track” peptides from the deep-research promotion set).

The case for prioritizing SS-31 on Alyve’s roadmap:

• 🎯 FDA-approved (Barth syndrome) — provides FDA-grade regulatory authority for the off-label catalog. Customers see “FDA-approved” and trust the broader catalog more.
• 475+ patients, zero serious AEs — exceptional safety story.
• Structural mechanism (no signaling) — fundamentally different safety calculus than every other peptide. Lifts directly into customer copy.
• Multi-disease application breadth — cognitive decline + TBI + early CKD + Long COVID + anti-aging + Barth.
• Cost-accessible at 5–10 mg/day — the Alyve compounded SubQ entry point makes the protocol sustainable at ~$150–300/month.
• No tachyphylaxis — continuous use is biologically fine; cycling is for skin/budget.

When SS-31 lands in the Alyve catalog, expect a 20 mg or 50 mg lyophilized vial with the same third-party Freedom Diagnostics COA (HPLC-UV purity + LC-MS identity confirmation) the rest of the line carries, at the same >99% purity standard Alyve has hit across all current 15 SKUs.

Why SS-31 needs a verified-COA vendor more, not less. SS-31 is a 4-amino-acid peptide with a positive net charge: easy to synthesize cheaply, but the counter-ion / salt form matters (TFA-salt contamination from synthesis is the recurring gray-market issue across the peptide world). Identity-confirmed, salt-form-disclosed, third-party-COA-tested SS-31 is the clean tier. Independent gray-market audits keep finding roughly 1 in 4 vials underdosed, mislabeled, or contaminated — that risk doesn’t go down just because the molecule is small. Alyve’s standard (US manufacturing + Freedom Diagnostics testing + >99% purity + lot-traceable) is the verified-clean tier the moment SS-31 lands.

Until SS-31 is in catalog, the practical pairing today is MOTS-c + NAD+ — the mitochondrial-derived signaling layer + the redox-support layer that SS-31 will sit on top of when it lands.

Use code OHM-15 for 15% off: Alyve’s pricing is very competitive, and buying 3 vials of any given peptide in one purchase gets you over 30% off retail. Three vials of SS-31 at the 5–10 mg/day protocol = roughly 3–6 months of continuous protocol — the natural commit-size.

Technical & analytical reference (chemistry & QC)

Molecular identity verified against PubChem (2026-06-23). SS-31 (elamipretide, MTP-131; brand name Forzinity, FDA-approved 2025 for Barth syndrome) is a synthetic tetrapeptide with two non-standard residues — D-arginine and 2’,6’-dimethyl-L-tyrosine — that drive both its cardiolipin-binding selectivity and its protease resistance.

Field	Value
Molecular formula	C₃₂H₄₉N₉O₅ (free base; PubChem CID 11764719)
Average MW	639.80 g/mol (free base)
CAS	736992-21-5 (free base); 1334953-95-5 (acetate)
Sequence	D-Arg-Tyr(2,6-diMe)-Lys-Phe-NH₂ (D-arginine at position 1, 2’,6’-dimethyl-L-tyrosine at position 2, C-terminal primary amide)
Class	Synthetic mitochondrial-targeted tetrapeptide; cardiolipin-binding antioxidant
Salt form	Clinical Forzinity formulation is the acetate salt; research-chem material may be TFA
HPLC purity criterion	RP-HPLC (C18, ACN/water + TFA), UV 220 nm; pharma-grade ≥98% main peak
MS identity	ESI-MS [M+H]⁺ m/z 640.4; ESI-MS [M+2H]²⁺ m/z 320.7; HRMS <5 ppm
Counterion / net peptide	Acetate (clinical) or TFA (research); peptide content ≥80% by Karl Fischer + counterion analysis; chiral verification of D-arginine is the dominant QC failure mode — gray-market material made with L-Arg instead of D-Arg loses protease resistance
Storage / reconstitution	Lyophilized −20 °C, desiccated, light-protected; reconstituted in bacteriostatic water 2–8 °C ≤14 days (C-terminal amide is hydrolysis-sensitive over time)
Degradation / stability	Pro/D-Arg/dimethyl-Tyr combination confers strong protease resistance and crosses the inner mitochondrial membrane to bind cardiolipin. Solution-state degradation: slow hydrolysis of the C-terminal amide; minimal oxidation (no Met or Cys present)

Primary references: Szeto 2006 (PMID 16855289) — original SS-peptide cardiolipin work; FDA Forzinity approval 2025 (Barth syndrome); Karaa et al. 2018 (PMID 30070644) MELAS Phase 2; PubChem CID 11764719.

Sources

• best-in-class single-source SS-31 content: FDA approval announcement, mitochondrial-derived vs mitochondrial-targeted taxonomy, cardiolipin-stabilization vicious-cycle mechanism, “structural support not signaling” safety framing, 475-patient zero-AE safety record, age-stratified protocol (don’t use under 50 without lab-confirmed dysfunction), oral-bioavailability di-/tri-peptide-transporter explanation, 5–10 mg/day cost-accessible protocol, compounding-pharmacy > research-use-only-site source preference (= Alyve verified-vendor framing).
• real-world lower-dose case-study data (N=5, 1–2 mg/day, 60–70 days): ATP5B +18.5 points average (vs. ~9.5 for MOTS-C on same platform); DRP1 +7 points (vs. ~13 for MOTS-C); glucose +8 points; 2 mg outperforms 1 mg; SLU-PP-332 as stacking partner; side effects minimal / injection-site lighter than MOTS-C. All.
• SS-31 was graded B/yellow PRIMARY energy + SECONDARY heal-recover. The FDA approval and ZERO serious AEs across 475+ patients justify upgrading to A/green for the Barth indication + maintaining B/green for off-label. Meta.js update pending.
• confirmed SS-31 is NOT in current 15-SKU catalog.
• 41520850 — Gudiksen A, Pilegaard H et al. 2026, Free Radical Biology and Medicine 246:682-696 — MOTS-c improves muscle mitochondrial efficiency + reduces ROS without increasing respiratory protein content; PGC-1α/AMPK dependent. The study that shifted the Mechanic Protocol from sequential to concurrent for the optimization tier.
• Holyfield 2026-07-14 Short: stacking update walkthrough + commercial note (concurrent Mechanic Protocol = MOTS-c at Alyve OHM-15 + SS-31 at US Pure Peptides OHM20, both at the same time).
• Froese 2026-07-25: anticardiolipin antibody immune-attack loop (cardiolipin leaks extracellularly → immune system attacks it → antibodies worsen mitochondrial damage); SS-31 as physical shield + outer membrane stabilization (mPTP); CFS anticardiolipin antibody connection; microvascular hypoperfusion as unifying mechanism for multi-organ SS-31 benefits (kidney/eye/brain/heart); urolithin A → SS-31 → MOTS-c three-step sequencing framework [OPINION].

Related: MOTS-c · NAD+ · Epithalon · Thymosin Alpha-1 · BPC-157 · Kisspeptin.